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Abstract
Background
Overweight and obesity are associated with increased risk of type 2 diabetes. Limited evi-
dence exists regarding the effect of excess weight on years lived with and without diabetes.
We aimed to determine the association of overweight and obesity with the number of years
lived with and without diabetes in a middle-aged and elderly population.
Methods and Findings
The study included 6,499 individuals (3,656 women) aged 55 y and older from the popula-
tion-based Rotterdam Study. We developed a multistate life table to calculate life expec-
tancy for individuals who were normal weight, overweight, and obese and the difference in
years lived with and without diabetes. For life table calculations, we used prevalence, inci-
dence rate, and hazard ratios (HRs) for three transitions (healthy to diabetes, healthy to
death, and diabetes to death), stratifying by body mass index (BMI) at baseline and adjust-
ing for confounders. During a median follow-up of 11.1 y, we observed 697 incident diabetes
events and 2,192 overall deaths. Obesity was associated with an increased risk of develop-
ing diabetes (HR: 2.13 [p < 0.001] for men and 3.54 [p < 0.001] for women). Overweight
and obesity were not associated with mortality in men and women with or without diabetes.
Total life expectancy remained unaffected by overweight and obesity. Nevertheless, men
with obesity aged 55 y and older lived 2.8 (95% CI −6.1 to −0.1) fewer y without diabetes
than normal weight individuals, whereas, for women, the difference between obese and nor-
mal weight counterparts was 4.7 (95% CI −9.0 to −0.6) y. Men and women with obesity lived
2.8 (95% CI 0.6 to 6.2) and 5.3 (95% CI 1.6 to 9.3) y longer with diabetes, respectively, com-
pared to their normal weight counterparts. Since the implications of these findings could be
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Conclusions
Obesity in the middle aged and elderly is associated with a reduction in the number of years
lived free of diabetes and an increase in the number of years lived with diabetes. Those extra
years lived with morbidity might place a high toll on individuals and health care systems.
Author Summary
WhyWas This Study Done?
• Obesity, which has contributed to a dramatic increase in type 2 diabetes, is one of today’s
highest public health concerns. Measures of lifetime consequences such as life expec-
tancy with and without diabetes are necessary to inform clinical care, patients, and
health care policy to facilitate the understanding of the consequences of being over-
weight or obese.
What Did the Researchers Do and Find?
• Using data from a well-defined European population with long-term follow-up, we cal-
culated life expectancy for individuals who were normal weight, overweight, and obese
and the difference in years lived with and without diabetes.
• We constructed three different health states: free of diabetes, diabetes, and death. We
further evaluated how participants in our study moved from one state to another (inci-
dent diabetes, incident mortality among diabetics, and mortality among nondiabetics) to
assess the difference in risk of mortality and diabetes among individuals 55 y and older
by different categories of body mass index (BMI).
• There were no differences in total life expectancy by body weight status. Nevertheless,
men with obesity lived 2.8 y fewer free of diabetes than their normal weight counter-
parts, whereas, for women, the difference between obese and normal weight subjects was
4.7 y. Moreover, men and women with obesity lived 2.8 and 5.3 more y with diabetes
compared to normal weight counterparts.
What Do These Findings Mean?
• Obesity increases the risk of developing diabetes earlier in life and the amount of years
individuals live with diabetes. As long as the obesity epidemic continues, we will observe
more individuals living with diabetes and for a longer period of time. Our findings
underscore the importance of preventing and treating obesity for clinicians, patients,
and policy makers.
Obesity, Life Expectancy, Type 2 Diabetes
PLOSMedicine | DOI:10.1371/journal.pmed.1002086 July 19, 2016 2 / 13
Organisation for Health Research and Development
(ZonMw); the Research Institute for Diseases in the
Elderly (RIDE); the Ministry of Education, Culture and
Science; the Ministry for Health, Welfare and Sports;
the European Commission (DG XII); and the
Municipality of Rotterdam. KD and JN are supported
by Erasmus Mundus Western Balkans (ERAWEB), a
project funded by the European Commission. OHF
works in ErasmusAGE, a center for aging research
across the life course funded by Nestlé Nutrition
(Nestec Ltd.) and Metagenics Inc. Nestlé Nutrition
(Nestec Ltd.) and Metagenics Inc. These funding
sources had no role in design and conduct of this
manuscript; collection, management, analysis, and
interpretation of the data; or preparation, review or
approval of this manuscript.
Competing Interests: OHF works in ErasmusAGE,
a center for aging research across the life course
funded by Nestlé Nutrition (Nestec Ltd.); Metagenics
Inc.; and AXA.
Abbreviations: BMI, body mass index; HR, hazard
ratio; IQR, interquartile range; METh, metabolic
equivalent hour; RS, Rotterdam Study; SD, standard
deviation; STROBE, Strengthening the Reporting of
Observational Studies in Epidemiology; T2D, type
two diabetes
Introduction
Overweight and obesity, which have contributed to a dramatic increase in type 2 diabetes, are
one of today’s highest public health concerns [1,2]. Previous estimates of the effect of obesity in
diabetes have been limited to absolute risks or lifetime risk without combining information
about quantity and quality of remaining years lived with or without the diabetes, raising a gap
in the intuitive understanding of risk and impact communicated among doctors and patients
[3]. Complementing current knowledge with comparative measures of the long-term dimen-
sions of disease, such as life expectancy, provides information on different scenarios, including
whether, for example, years with disease are increasing but the proportion of life spent free of
disease is increasing or decreasing. Moreover, quantification of these estimates has been exten-
sively recommended to help inform public health interventions [4].
Studies evaluating the association between obesity and life expectancy have shown that obe-
sity in adulthood is associated with a decrease in life expectancy of approximately 6–13 y [5,6].
Two United States studies using data from National Health Surveys showed that obesity in
adulthood was associated not only with reduced life expectancy but also with a reduced num-
ber of years lived free of diabetes and cardiovascular disease in men and women [7,8]. Specifi-
cally, the study by Grover et al. showed that obesity in individuals aged 40–59 y was associated
with a shorter life expectancy free of diabetes and cardiovascular disease by 5.9 y in men and
10.3 y in women [7]. Notably, this study did not distinguish between life expectancy with and
without diabetes. The study performed by Narayan et al., which primarily focused on the effect
of obesity on lifetime risk of diabetes, reported that individuals with obesity had an earlier
onset of diabetes during their lifespan and spent more years lived with diabetes [8]. Neverthe-
less, both studies do not provide a direct observation of a well-defined population, as the results
are obtained by modelling and simulation.
Therefore, we aimed to calculate the association of overweight and obesity with total life
expectancy and years lived with and without diabetes at 55 y of age. We constructed multistate
life tables using data collected from 1997–2001 and with over 14 y of follow-up from the Rot-
terdam Study.
Methods
Ethical Considerations
The Rotterdam Study has been approved by the medical ethics committee according to the
Population Screening Act: Rotterdam Study, executed by the Ministry of Health, Welfare and
Sports of the Netherlands. All participants in the present analysis provided written informed
consent to participate and to obtain information from their treating physicians.
Study Population
This study was embedded within the framework of the Rotterdam Study (RS), a prospective
cohort study of the community-dwelling population in Rotterdam, Netherlands. The objectives
and design of the Rotterdam Study have been described in detail elsewhere [9]. In response to
demographic changes leading the acceleration of population aging, the Rotterdam Study was
originally designed to investigate determinants of disease occurrence and progression in the
elderly. In addition to contributing to the understanding of the etiology of geriatric illnesses,
the study is expected to lead to specific recommendations for intervention. Following the pilot
in 1989, recruitment started in January 1990 of all residents aged 55 y or older, of whom 7,983
(78%) agreed to participate (RS Cohort I. The study was extended in 2000, with a second
cohort of individuals (RS-II) who had reached the age of 55 y or moved into the study area.
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For the current study, we used data from the participants attending the third examination
of the original cohort (RS-I visit 3, 1997–1999; n = 4,797) and the participants attending the
first examination of the extended cohort (RS-II visit 1, 2000–2001; n = 3,011).
We excluded participants who did not visit the research center, did not have information on
body mass index (BMI; n = 1,051) or no information on smoking behavior (n = 40). To account
for disease-related weight loss, we excluded participants who had BMI< 18.5 (n = 51). Individ-
uals without informed consent (n = 30) or those who did not have diabetes follow-up informa-
tion (n = 137) were further excluded. Finally, 6,499 participants (3,656 women) were available
for the current analysis.
Assessment of Anthropometric Measurements, Health Behaviors, and
Laboratory Measurements
Anthropometrics were measured in the research center by trained staff. Height and weight
were measured with the participants standing without shoes and heavy outer garments. BMI
was calculated as weight divided by height squared (kg/m2) [10]. According to the WHO cut-
off criteria, we composed BMI as a categorical variable with three categories: normal weight
(18.5 BMI< 25), overweight (25 BMI< 30) and obese (30 BMI).[10]. For our data
analysis, obesity was grouped into a single category of BMI of 30.0 and higher because of
the small sample size in each obesity class (e.g., 30< BMI 35 and 35< BMI< 40 and
BMI 40). Smoking status was categorized as current smoker, former smoker, and never
smoker, and additionally, for current smokers, we accounted for cigarettes smoked per day.
Information on education was assessed according to the standard international classification of
education and was composed into four categories: elementary education, lower secondary edu-
cation, higher secondary education, and tertiary education [11]. Marital status was divided into
single, married, widowed, or divorced/separated. Physical activity was measured by question-
naire and expressed in metabolic equivalent hours (METh)/week. For analysis, we divided the
population into three equal groups (tertile) [12]. Alcohol consumption was categorized as less
than 1 glass/d, 1–4 glasses/d for men and 1–2 glasses/d for women, and>4 glasses/d for men
and>2 glasses/d for women. Comorbidity was considered present when “non-obesity-related
cancers other than skin cancer” or chronic obstructive pulmonary disease was prevalent at
baseline. From baseline comorbidities, we excluded cancers associated with obesity [13] and
cancers that are curable and not likely to be related to weight loss or mortality, such as skin
cancer [14]. Cancers induced by obesity are in the pathway between obesity and mortality;
therefore, we accounted them as mediators. Chronic obstructive pulmonary disease was
defined as a type of obstructive lung disease characterized by airflow limitation that is not fully
reversible [15]. Chronic obstructive pulmonary disease has been shown to be accompanied
with weight loss [16].
Hypertension, dyslipidemia, and cardiovascular disease were also considered as mediators,
and therefore, we did not adjust for them in the main analyses. However, to investigate the
independent association of obesity on diabetes and mortality, we conducted an additional sen-
sitivity analysis by adjusting in the multivariable analysis for comorbidities including chronic
obstructive pulmonary disease, all cancers, and cardiovascular disease at baseline. The presence
of hypertension and dyslipidemia was based on medication information, whereas cardiovascu-
lar disease was defined as the presence of one or more definite manifestations of coronary
heart disease (coronary revascularization, nonfatal or fatal myocardial infarction, or death due
to coronary heart disease), stroke, and heart failure [17–19].
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Assessment of Outcome
Participants were followed up from the date of baseline center visit onwards. At baseline and
during follow-up, cases of diabetes were ascertained by use of general practitioners’ records
(including laboratory glucose measurements), hospital discharge letters, and serum glucose
measurements from Rotterdam Study visits, which take place roughly every 4 y [20]. Diabetes
was defined according to recent WHO guidelines [21] as a fasting serum blood glucose 7.0
mmol/L, a nonfasting blood glucose 11.1 mmol/L (when fasting samples were not available),
or the use of blood-glucose-lowering medication. Information regarding the use of blood-
glucose-lowering medication was ascertained from both structured home interviews and link-
age to pharmacy records [21]. All potential prevalent cases of diabetes were independently
reviewed by two study physicians. In case of disagreement, consensus was reached with an
endocrinologist.
Statistical Analysis
We did not publish or preregister a plan for this study. The analysis plan is described below,
with any differences noted in S1 Text. To calculate the life expectancy with and without diabe-
tes in normal weight, overweight, and obese groups, we created a multistate life table, which is
a demographic tool that allows the experience of individuals in different health states to be
combined in order to calculate the total life expectancy and the amount of years that individu-
als could expect to live in the different health states [22]. We constructed three different health
states: free of diabetes, diabetes, and death. The possible transition directions were from free of
diabetes to diabetes (incident diabetes), free of diabetes to death (mortality among nondiabet-
ics), and from diabetes to death (mortality among diabetics). No backflows were allowed, and
only the first event into a state was considered.
To obtain transition rates, we calculated the overall age- and sex-specific rates for each tran-
sition. Next, we calculated the prevalence of normal weight, overweight, and obesity by sex, by
10-y age groups, and separately for subjects with and without diabetes. Subsequently, we com-
puted gender-specific hazard ratios (HRs) comparing overweight and obese individuals to
normal weight individuals by using Poisson regression with “Gompertz” distribution in two
models. Model 1 was adjusted for age, and Model 2 was adjusted for age, smoking status, ciga-
rettes smoked per day (for current smokers), alcohol consumption, education, marital status,
physical activity, and comorbidities (non-obesity-related cancers other than skin cancer or
chronic obstructive pulmonary disease).
Finally, transition rates were calculated for each category of BMI separately using (a) the
overall transition rates, (b) the adjusted HRs (model 2) for diabetes and mortality, and (c) the
prevalence of normal weight, overweight, and obesity by sex and with and without diabetes.
Similar calculations have been described previously [23,24]. The multistate life table started at
age 55 y and closed at age 100 y.
We used Monte Carlo simulation (parametric bootstrapping) with 10,000 runs to calculate
the confidence intervals of our life expectancy estimates with @RISK software (Palisade) [25].
To exclude any potential bias caused by smoking or comorbidities at baseline, we repeated
the analysis among those who were both nonsmokers and without comorbidities (n = 5,018).
Additionally, we estimated the life expectancy among participants without hypertension, dysli-
pidemia, and cardiovascular disease at baseline (n = 3,843). To account for possible reverse
causation, we estimated the HRs after excluding diabetes events (n = 64) or deaths (n = 186)
during the first 2 y of follow-up. Moreover, as a sensitivity analysis, we excluded the individuals
with BMI< 22 (n = 448) to provide more conservative estimates of overweight and obesity in
association with mortality.
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To deal with missing values (less than 5%) for covariables including education, living situa-
tion, income, and alcohol, we used single imputation with the expectation maximization
method in SPSS (IBM SPSS Statistical for Windows, Armonk, New York: IBM). This method
allowed us to impute the missing values as a function of other variables by using regression
methods. We used STATA version 13 for Windows (StataCorp, College Station, Texas) and R
statistical software (A language and environment for statistical computing; R Foundation for
Statistical Computing, Vienna, Austria) for our analysis.
Results
The final study population consisted of 6,499 individuals: 2,843 men and 3,656 women. In
total, we observed 697 (12.4%) incident diabetes events and 2,192 (33.7%) overall deaths over
14 y of follow-up. The mean age of the population was 69.2. Compared to women, men at base-
line were younger, consumed higher alcohol amounts, and smoked more but showed lower lev-
els of BMI and physical activity. While more women were on treatment for hypertension, more
men were treated for dyslipidemia. Furthermore, the prevalence of cardiovascular disease and
other comorbidities was higher among men (Table 1).
Diabetes Events and Death
Table 2 shows the HRs of the association between BMI categories with risk of incident diabetes
and mortality among men and women. In multivariable adjusted model, obesity (BMI higher
than 30) was associated with an increased risk of incident diabetes in men (HR 2.13, 95% CI
1.48–3.07, p< 0.001) and women (HR 3.54, 95% CI 2.64–4.75, p< 0.001) comparing with nor-
mal weight individuals (Table 2).
The association between obesity and mortality among those without diabetes was not statis-
tically significant for both men (HR 1.00, 95% CI 0.78–1.28, p = 0.994) and women (HR 0.89,
95% CI 0.74–1.06, p = 0.198). Similarly, we did not find significant associations between obesity
and mortality among individuals with diabetes. The corresponding HRs and 95% CI are 0.79
(0.56–1.11, p = 0.173) for men and 0.70 (0.55–1.01, p = 0.051) for women (Table 2).
Total Life Expectancy and Life Expectancy with and without Diabetes
The association between normal weight, overweight, and obesity with the risk of each transi-
tion was translated into number of years lived with and without diabetes (Fig 1 and Table 3).
Total life expectancy for men and women with overweight and obesity were not significantly
different than normal weight counterparts. Compared to normal weight men, the life expec-
tancy of 55-y-old men in the obese group was 0.0 y (95% CI −1.3 to 1.3). For women, these dif-
ferences were 0.7 (95% CI −0.3 to 1.6) y (Table 3). For both men and women, obesity was
associated with fewer years lived without diabetes and more years lived with diabetes than their
normal weight counterparts. Men and women with obesity lived 2.8 (95% CI −6.1 to −0.1) and
4.7 (95% CI −9.0 to −0.6) fewer y without diabetes, respectively, than those in the normal
weight group. Additionally, men and women with obesity lived more years with diabetes than
their normal weight counterparts: 2.8 (95% CI 0.6 to 6.2) y for men and 5.3 (95% CI 1.6 to 9.3)
y for women (Fig 1 and Table 3).
Total life expectancy and number of years lived with and without diabetes for normal
weight, overweight, and obese individuals who are non-smokers and without prevalent comor-
bidities (“non-obesity-related cancers other than skin cancer” and chronic obstructive pulmo-
nary disease) are presented in S1 Fig, and for individuals without hypertension, dyslipidemia,
and cardiovascular disease, they are presented in S2 Fig. As expected, compared to the overall
population included in the main analyses, total life expectancy was higher for individuals who
Obesity, Life Expectancy, Type 2 Diabetes
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were nonsmokers and without comorbidities at baseline and for individuals without cardiovas-
cular disease, hypertension, and dyslipidemia. However, differences in years lived with and
without diabetes among normal weight, overweight, and obese individuals were overall similar
to those found in the total population. S1 Table shows the baseline characteristics of individuals
who did not visit the research center or without BMI information. Individuals in this subgroup
were older than the individuals included in the study and were less physically active. Addition-
ally, when we repeated the main analysis after excluding incident diabetes and deaths during
the first 2 y of follow-up (S2 Table), excluding individuals with BMI< 22 (S3 Table), or
Table 1. Baseline characteristics of study population (n = 6,499).
Characteristics Men Women
Population
n 2,843 (43.7) 3,656 (56.3)
Age at interview (years) 68.7 (7.9) 69.6 (8.4)
Anthropometry
BMI, kg/m2 26.6 (3.2) 27.4 (4.4)
Normal (BMI 18.5–25) 927 (32.6%) 1,174 (32.1%)
Overweight (BMI 25–30) 1,525 (53.6%) 1,575 (43.1%)
Obese (BMI 30+) 391 (13.8%) 907 (24.8%)
Social Economic Status
Marital status
Single 83 (2.9%) 254 (6.8%)
Married 2,247 (79.0%) 1,958 (53.6%)
Widowed 306 (10.8%) 1,069 (29.2%)
Divorced/separated 207 (7.3%) 375 (10.3%)
Education
Elementary 268 (9.4%) 599 (16.4%)
Lower secondary 853 (30.0%) 1,953 (53.4%)
Higher secondary 1,109 (39.0%) 863 (23.6%)
Tertiary 613 (21.6%) 241 (6.6%)
Lifestyle Variables
Smoking
Never smoker 910 (32.0%) 2,266 (62.0%)
Former smoker 1,417 (49.8%) 780 (21.3%)
Current smoker 516 (18.1%) 610 (16.7)
Daily cigarettes smoked 2.8 (7.0) 2.3 (6.1)
Alcohol (drinks/d)
<1 glass/d 1,270 (44.7%) 2,601 (71.1%)
1–4 glasses/d (men); 1–2 glasses/d(women) 1,340 (47.1%) 658 (18.0%)
>4 glasses/d (men); >2 glasses/d(women) 233 (8.2%) 397 (10.9%)
Physical activity (METh) 74.0 (43.8) 92.6 (43.1)
Treatment for Hypertension 604 (22.2%) 909 (26.1%)
Treatment for Dyslipidemia 410 (14.4%) 456 (12.5%)
Comorbidities (Cancer a and Chronic Obstructive Pulmonary Disease) 270 (9.5%) 204 (5.6%)
Prevalence of Cardiovascular Disease 573 (20.2) 303 (8.3%)
BMI, body mass index; METh, metabolic equivalent hour. Values are means (standard deviations [SDs]) or
numbers (percentages) or median (interquartile range [IQR]).
a Cancer includes “non-obesity-related cancers other than skin cancer.”
doi:10.1371/journal.pmed.1002086.t001
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adjusting for all comorbidities (all cancers, cardiovascular disease, and chronic obstructive pul-
monary disease) (S4 Table), we found generally similar results to the main analyses.
Discussion
Overweight and obesity at age 55 y and older represent not only a significant increase in the
risk of developing diabetes but also an important decrease in the number of years lived free of
diabetes and an extended number of years lived with diabetes when compared with normal
weight counterparts. While total life expectancy remained unaffected, on average, obesity was
associated with 2.8 fewer y lived free from diabetes in men and 4.7 fewer y in women. Addition-
ally, obese men and women respectively lived 2.8 and 5.3 y longer with diabetes compared to
their normal weight counterparts.
Table 2. Hazard ratios for incidence diabetes and death in overweight and obesemen and women.
Men Women
Transition Categories Cases, Number/
Person-Years
Model 1 HR
(95% CI)a
Model 2 HR
(95% CI)b
Cases, Number/
Person-Years
Model 1 HR
(95% CI)a
Model 2 HR
(95% CI)b
Incident T2D Normal
weight
297/23,110 1.0 (Reference) 1.0 (Reference) 400/33,152 1.0 (Reference) 1.0 (Reference)
Overweight 1.45 (1.10–1.90) 1.52 (1.15–2.00) 2.27 (1.72–3.00) 2.32 (1.76–3.06)
Obese 2.00 (1.40–2.87) 2.13 (1.48–3.07) 3.47 (2.60–4.65) 3.54 (2.64–4.75)
Mortality among
Those without T2D
Normal
weight
858/24,527 1.0 (Reference) 1.0 (Reference) 837/35,227 1.0 (Reference) 1.0 (Reference)
Overweight 0.97 (0.84–1.13) 1.02 (0.88–1.18) 0.82 (0.71–0.96) 0.85 (0.76–0.99)
Obese 0.96 (0.75–1.22) 1.00 (0.78–1.28) 0.86 (0.72–1.03) 0.89 (0.74–1.06)
Mortality among
Those with T2D
Normal
weight
335/5,259 1.0 (Reference) 1.0 (Reference) 253/6,237 1.0 (Reference) 1.0 (Reference)
Overweight 0.90 (0.70–1.15) 0.99 (0.77–1.28) 0.75 (0.54–1.04) 0.77 (0.55–1.09)
Obese 0.77 (0.55–1.07) 0.79 (0.56–1.11) 0.72 (0.51–1.02) 0.70 (0.55–1.01)
HR, hazard ratio; T2D, type two diabetes.
a Adjusted for age.
b Adjusted for age, smoking, cigarettes smoked per day for current smokers, education level, marital status, physical activity, alcohol use, and comorbidities
(“non-obesity-related cancers other than skin cancer” or chronic obstructive pulmonary disease).
doi:10.1371/journal.pmed.1002086.t002
Fig 1. Life expectancy with and without diabetes at age 55 y for different weight categories. BMI
categories: normal weight BMI is <25 kg/m2, overweight BMI is 25–30 kg/m2, and obese BMI is30 kg/m2.
DM, type 2 diabetes mellitus; LE, life expectancy.
doi:10.1371/journal.pmed.1002086.g001
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Years lived free of diabetes are a result of two components: incidence of diabetes and mor-
tality in those without diabetes. We observed a higher risk of incident diabetes in overweight
and obese individuals when compared to their normal weight counterparts, which could reflect
an earlier diagnosis of diabetes across lifespan. Furthermore, a higher risk of mortality in those
without diabetes will result in a decrease of total life expectancy and consequently will shorten
years lived free of diabetes. The number of years lived with diabetes is a consequence of inci-
dent diabetes risk and mortality risk among those with diabetes. Higher incidence of diabetes
would lead to an earlier occurrence of diabetes, whereas lower risk of mortality among those
with diabetes would lead to greater number of years lived with diabetes.
Our analysis indicated that overweight and obesity increased the risk of diabetes for both
men and women, and the HRs were comparable with other studies [26,27]. Additionally, we
showed that overweight and obesity were not associated with mortality in individuals with
and without diabetes. A recent meta-analysis including diabetic populations revealed a lower
risk of mortality among overweight and obese subjects than normal weight counterparts [28].
Although our estimates of mortality risk among diabetic patients are similar to the meta-analy-
sis, we cannot support the protective effect of obesity on mortality until further research is
done.
In our study, total life expectancy in individuals aged 55 y and over for both men and
women remained unaffected by overweight and obesity. In contrast, an earlier study using Fra-
mingham Study data has showed that at the age of 40 y, obesity was associated with large
decreases in total life expectancy [6]. This discrepancy could be explained by the difference in
participants’ age (55 versus 40) in life expectancy calculations and differences in the calendar
time of baseline measurements (1997 versus 1948). Given the improvements in prevention and
treatment of cardiometabolic risk factors in the last decade, the association of obesity with mor-
tality has diminished substantially [29,30]. Consistent with our findings, recent data among the
middle-aged and elderly has demonstrated that overweight and obesity are not associated with
a reduction in life expectancy [31,32]. Nevertheless, our study extended the previous evidence
by calculating the association of obesity in life expectancy with and without diabetes. We
Table 3. Differences in life expectancy, in years, at age 55 y for normal weight, overweight, and obesity in men and women.
Total LE Difference in Total
Life Expectancy
Life Expectancy
Free of Diabetes
Differences in Number of
Years Lived Free of
Diabetes
Life Expectancy
with Diabetes
Differences in Number of
Years Lived with Diabetes
Men
Normal
Weight
27.3 (26.7
to 27.9)
Ref 24.9 (24.1 to 25.7) Ref 2.4 (1.9 to 3.0) Ref
Overweight 26.9 (26.5
to 27.5)
−0.4 (−1.2 to 0.5) 23.4 (22.6 to 24.4) −1.5 (−2.7 to −0.1) 3.5 (2.8 to 4.1) 1.1 (0.2 to 2.2)
Obese 27.3 (26.0
to 28.6)
0.0 (−1.3 to 1.3) 22.1 (19.1 to 24.7) −2.8 (−6.1 to −0.1) 5.2 (3.1 to 7.9) 2.8 (0.6 to 6.2)
Women
Normal
Weight
31.5 (31.1
to32.1)
Ref 29.4 (28.4 to 30.5) Ref 2.1 (1.3 to 2.9) Ref
Overweight 32.4 (31.8
to 33.1)
0.9 (0.1 to 1.7) 27.4 (25.5 to 29.6) −2.1 (−4.3 to 0.1) 5.1 (3.1 to 6.7) 3.0 (1.1 to 4.8)
Obese 32.2 (31.3
to 33.0)
0.7 (−0.3 to 1.6) 24.8 (21.1 to 28.5) −4.7 (−9.0 to −0.6) 7.4 (4.0 to 10.8) 5.3 (1.6 to 9.3)
LE, life expectancy; Ref, Reference. We calculated the differences for total life expectancy and years lived with and without diabetes by subtracting the
estimates of overweight and obese individuals from those of normal weight individuals.
doi:10.1371/journal.pmed.1002086.t003
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demonstrated that obesity increases the risk of developing diabetes earlier in life and further
extends years lived with diabetes. These findings support previous results from a study by
Narayan et al. [8], which used data from the US National Health Survey. However, our study is
unique regarding the approach used for estimating life expectancy with and without diabetes.
While Narayan et al. obtained the estimates by modelling and simulation, we calculated the life
expectancy with and without diabetes from direct observation of a well-defined population
using multistate life tables. Moreover, the study by Narayan et al. used self-reported data for
the diagnosis of diabetes and information on height and weight, whereas in our study we had
well-ascertained diabetes diagnoses obtained from physicians and linkage to pharmacy data
and weight and height measured by trained research assistants at the study center.
In our study, we noted a difference in the number of years lived with diabetes among men
and women. Compared to men, women had an increased risk of diabetes by BMI, indicating
an earlier occurrence of diabetes during their life. Moreover, women with diabetes had a lower
risk of mortality compared to men. Taken these results together, we could explain why women
spend more years with diabetes than men. This is in accordance with previous research con-
ducted in the US concluding that women spend more years living with diabetes than men [8],
possibly due to larger differences in probabilities of death between males and females observed
for patients with diabetes relative to those without diabetes [33].
Strengths of the current study include the use of data from a prospective, well-organized
study with long-term follow-up. The diagnosis of incident diabetes was done by standardized
blood glucose measurements at the repeated study center visits and electronic linkage with
pharmacy dispensing records in the study area. Height and weight were measured in the
research center by trained staff. Nevertheless, some limitations of this study should be
addressed. In our analysis, we excluded individuals with missing information on weight and
height since the BMI is our main exposure. This subgroup was older and less physically active.
Furthermore, since the generalizability of these findings could be limited to middle-aged and
older white European populations, our results need confirmation in other populations. Addi-
tionally, studies evaluating the association of obesity with mortality could be prone to incorrect
adjustment for confounders such as smoking or weight loss related to comorbidities. In our
study, we adjusted for smoking status and the cigarettes smoked per day and comorbidities.
Moreover, we conducted a sensitivity analysis to take into account reverse causation by exclud-
ing events during the first 2 y of follow-up.
The added value of this study is the combination of the observed effects of obesity on diabe-
tes incidence and mortality translated into population measures such as life expectancy with
and without diabetes that might be important to clinicians, patients, and policy makers in tack-
ling the next stages of obesity epidemics. Our study showed that among middle-aged and
elderly individuals, total life expectancy was not different for those who were overweight or
obese. Obesity is associated with earlier and extended periods lived with diabetes. Those extra
years of life will be filled with an expansion of accompanying comorbidities, placing a higher
toll on clinicians and health care systems and challenging the new global strategies for obesity
and diabetes prevention.
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